Literature DB >> 1956044

Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype.

C J Blankley1, J C Hodges, S R Klutchko, R J Himmelsbach, A Chucholowski, C J Connolly, S J Neergaard, M S Van Nieuwenhze, A Sebastian, J Quin.   

Abstract

Structure-activity relationships are reported for a novel class of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid derivatives that displace 125I-labeled angiotensin II from a specific subset of angiotensin II (Ang II) binding sites in rat adrenal preparations. This binding site is not the Ang II receptor mediating vascular contraction or aldosterone release, but, rather, is one whose function has not yet been fully elucidated. It has been identified in a number of tissues and has a similar affinity for Ang II and its peptide analogues as does the vascular receptor. The non-peptide compounds reported here are uniquely specific in displacing Ang II at this binding site and are inactive in antagonizing Ang II at the vascular receptor or in pharmacological assays measuring vascular effects. PD 123,319 (79), one of the most potent compounds, has an IC50 of 34 nM. Certain of these compounds may have utility in the definition and study of Ang II receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1956044     DOI: 10.1021/jm00115a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Effect of luminal angiotensin II receptor antagonists on proximal tubule transport.

Authors:  A Quan; M Baum
Journal:  Am J Hypertens       Date:  1999-05       Impact factor: 2.689

2.  Cardiovascular responses elicited by a new endogenous angiotensin in the nucleus tractus solitarius of the rat.

Authors:  Vineet C Chitravanshi; Hreday N Sapru
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

3.  The hypothalamic arcuate nucleus: a new site of cardiovascular action of angiotensin-(1-12) and angiotensin II.

Authors:  Hideki Arakawa; Vineet C Chitravanshi; Hreday N Sapru
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-24       Impact factor: 4.733

4.  Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.

Authors:  Vidya Narayanaswami; Sucharita S Somkuwar; David B Horton; Lisa A Cassis; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

5.  Saralasin and Sarile Are AT2 Receptor Agonists.

Authors:  Marie-Odile Guimond; Mathias Hallberg; Nicole Gallo-Payet; Charlotta Wallinder
Journal:  ACS Med Chem Lett       Date:  2014-08-18       Impact factor: 4.345

Review 6.  AT2 receptor activities and pathophysiological implications.

Authors:  Luis C Matavelli; Helmy M Siragy
Journal:  J Cardiovasc Pharmacol       Date:  2015-03       Impact factor: 3.105

7.  The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats.

Authors:  Zeynep Ulutas; Necip Ermis; Onural Ozhan; Hakan Parlakpinar; Nigar Vardi; Burhan Ates; Cemil Colak
Journal:  Cardiovasc Toxicol       Date:  2020-07-09       Impact factor: 3.231

8.  Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory.

Authors:  J Shepherd; D J Bill; C T Dourish; S S Grewal; A McLenachan; K J Stanhope
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

9.  Cardiovascular effect of angiotensin-(1-12) in the caudal ventrolateral medullary depressor area of the rat.

Authors:  Tetsuya Kawabe; Kazumi Kawabe; Hreday N Sapru
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-27       Impact factor: 4.733

10.  Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways.

Authors:  Aung Than; Melvin Khee-Shing Leow; Peng Chen
Journal:  J Biol Chem       Date:  2013-04-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.